Evaluation of rapid antigen detection kits for detection of SARS-CoV-2 B.1.617.2 virus

Gannon CK Mak*,1, Stephen SY Lau1, Kitty KY Wong1, Nancy LS Chow1, Chi-Shan Lau1, Edman TK Lam1, Ken HL Ng1 & Rickjason CW Chan1
1Microbiology Division, Public Health Laboratory Services Branch, Centre for Health Protection, Department of Health, Hong Kong Special Administrative Region, China
*Author for correspondence: sophls10@dh.gov.hk

Aim: Currently, there is lack of data regarding rapid antigen detection (RAD) kits to detect SARS-CoV-2 B.1.617.2 virus. Objective: The purpose of this evaluation is to assess analytical sensitivity of 12 RAD kits against SARS-CoV-2 B.1.617.2. Study design: Analytical sensitivity was determined by limit of detection (LOD). A serial tenfold dilution set from a respiratory specimen collected from a COVID-19 patient infected by SARS-CoV-2 B.1.617.2 was used. RT-PCR was used as a reference method. Results: The LOD results showed that 11 and one RAD kits were 100- and 1000-fold less sensitive than RT-PCR respectively. Conclusion: The results showed that the RAD kits evaluated in this study may be used for first-line screening of the SARS-CoV-2 B.1.617.2 variant.

First draft submitted: 28 September 2021; Accepted for publication: 14 March 2022; Published online: 11 April 2022

Keywords: SARS-CoV-2 • COVID-19 • B.1.617.2 • delta • rapid antigen detection

The gold standard to detect SARS-CoV-2 is RT-PCR. However, it takes hours to detect the nucleic acid from RNA extraction, amplification to results interpretation. In addition, specialized instrument and expertise are required. Rapid antigen detection (RAD) kits are alternative to RT-PCR due to the fast results and are easy to use, although these kits are inferior to RT-PCR in terms of sensitivity [1]. RAD kits detect viral protein by the immobilized coated SARS-CoV-2 antibody on the device. Data on specificity for the currently available RAD kits were consistently reported to be high [2]. The main disadvantages of this assay are the lack of amplification steps. Therefore, sensitivity of RAD kits cannot be comparable to RT-PCR. In addition, the performance of different RAD kits varied between different brands [3–8].

SARS-CoV-2 is continuously evolving, WHO classified SARS-CoV-2 as variants of concern (VOCs) for those having global public health impacts. At the time of writing this report, there are four VOCs, namely, B.1.1.7, B.1.351, P.1 and B.1.617.2, according to the PANGO nomenclature system [9–11]. SARS-CoV-2 B.1.617.2 is particularly important due to its high transmissibility. Moreover, this VOC is dominating worldwide when comparing with the other three VOCs [12–14]. In Hong Kong, due to the stringent containment strategies implemented [15], the daily number of COVID-19 cases remained to be low from May 2021 onwards and majority of them were limited to the imported cases [16] which was in contrast to 2020 [17,18]. To track variants, there is an intensive surveillance system which can detect VOCs circulating worldwide. Although rare, the author’s system was capable of detecting local community acquired VOCs [19,20].

VOCs may affect the effectiveness of different diagnostic assays [21]. The possibility of impacts on RAD kits have been assessed for VOCs. Overall, most RAD kits can detect VOCs, minority differences were observed for some VOCs in terms of sensitivity [22,23]. For the recently emerged SARS-CoV-2 B.1.617.2, there is scant data on the parallel comparison between RAD kits. The purpose of this evaluation is to assess analytical sensitivity of RAD kits against SARS-CoV-2 B.1.617.2.
Table 1. Rapid antigen detection kits evaluated in the present study.

| Kit                          | Manufacturer                          | Country of manufacturer | Code | Sample type                                      | Target                         | Turnaround time |
|------------------------------|---------------------------------------|-------------------------|------|-------------------------------------------------|--------------------------------|-----------------|
| Roche SARS-CoV-2 Rapid Antigen Test† | SD BIOSENSOR                         | Republic of Korea       | N01  | Nasopharyngeal swab, specimens in transport media | Nucleocapsid                    | 15–30 mins      |
| Panbio COVID-19 Ag Rapid Test Device† | Abbott Rapid Diagnostics Jena GmbH    | Germany                 | N02  | Nasopharyngeal swab                             | Not specified                  | 15–20 mins      |
| INDICAID COVID-19 Rapid Antigen Test | PHAGE Scientific International Ltd  | Hong Kong SAR            | N03  | Nasal swab, nasopharyngeal swab                 | Not specified                  | 20–25 mins      |
| Aegle Coronavirus Ag Rapid Test Cassette | Zhejiang Orient Gene Biotech Co., Ltd | China                   | N04  | Nasopharyngeal swab                             | Nucleocapsid                    | 15–20 mins      |
| BIOSYNEX COVID-19 Ag BSS       | BIOSYNEX SWISS SA                     | Switzerland              | N05  | Nasopharyngeal swab                             | Nucleocapsid                    | 15–20 mins      |
| CLINITEST Rapid COVID-19 Antigen Test | Healgen Scientific Limited Liability Company | USA                   | N06  | Nasopharyngeal swab                             | Nucleocapsid                    | 15–20 mins      |
| COVID-19 Antigen Test Kit      | Nantong Diagnos Biotechnology Co., Ltd | China                   | N07  | Nasal swab, throat swab                         | Nucleocapsid                    | 10–15 mins      |
| Rapid SARS-CoV-2 Antigen Test Card | MP Biomedicals Germany GmbH            | Germany                 | N08  | Nasal swab, nasopharyngeal swab, oropharyngeal swab | Nucleocapsid                    | 15–20 mins      |
| SARS-CoV-2 Virus Antigen Detection Kit | BGI PathoGenesis Pharmaceutical Technology Co., Ltd | China | N09  | Nasal swab                                      | Not specified                  | 15–20 mins      |
| AUSET COVID-19 Antigen Rapid Test Kit – New Saliva Test | Beijing Kewei Clinical Diagnostic Reagent Inc. | China | N10  | Saliva secretion, oropharyngeal secretion       | Nucleocapsid                    | 15–20 mins      |
| Rapid SARS-COV-2 Antigen Test Card | Ximan Boson Biotech Co., Ltd         | China                   | N11  | Nasopharyngeal swab                             | Nucleocapsid                    | 15–20 mins      |
| COVID-19 Antigen Saliva Test   | ulti med Products (Deutschland) GmbH | Germany                 | N12  | Saliva                                          | Nucleocapsid                    | 10 mins         |

This table was prepared by retrieving information from the manufacturer inserts delivered together with the kits.

†WHO Emergency Use listing for in vitro diagnostics detecting SARS-CoV-2.

‡For the ease of communication throughout the article, each kit was assigned a code from N01 to N12.

Materials & methods

SARS-CoV-2 B.1.617.2 virus

The Public Health Laboratory Services Branch (PHLSB) in Hong Kong has been designated as WHO COVID-19 reference laboratory since April 2020 and all confirmed cases in Hong Kong were either diagnosed or confirmed by PHLSB [24]. The leftover of the respiratory specimens after RNA extraction were stored at -70°C. From 7 January to 27 June 2021, PHLSB detected 77 SARS-CoV-2 B.1.617.2 cases in Hong Kong [20]. A respiratory specimen, combined nasopharyngeal and throat swabs, obtained from a COVID-19 patient collected on 12 May 2021 (hCoV-19/Hong Kong/VM21025593/2021) was selected for this evaluation. This specimen had sufficient quantity (>500 μl) and high viral load (Ct <20) which fulfil the criteria for this evaluation.

RAD kits for SARS-CoV-2 detection

We routinely reviewed and evaluated RAD kits that were introduced to the authors' lab by local suppliers [7,8,25–27]. A total of 12 RAD kits were selected. Prior to this evaluation, we performed a screening and found that all of them shared similar analytical performance when tested against the SARS-CoV-2 culture isolate, the first SARS-CoV-2 case detected in Hong Kong (data not shown). The nucleotide sequence showed that it shared 99.97% identity with the strain WIV04 (GISAID accession number EPI_ISL_402124) detected in Wuhan, China, in late 2019 [28]. The nucleocapsid (N) protein was 100% identical to WIV04. The details for each kit was summarized in Table 1. For the ease of communication, these kits were coded arbitrary from N01 to N12. N01–N06 were procured by the authors. The remaining six kits, N07–N12, were introduced to the author's lab by local suppliers during the period from December 2020 to June 2021 and were gifted by them for this evaluation. N01 and N02 were under the ‘WHO Emergency Use listing for in vitro diagnostics detecting SARS-CoV-2’ [29].

The kits selected were based on lateral flow principles. SARS-CoV-2 antibody was immobilized coated on the test cassettes which can detect viral antigen. The test results can be interpreted by the naked eye. The test results were assessed and read by two technicians. Results grading of the band intensity were based on a previous study [23]. In case of doubtful results, the third technician interpreted the test results.
Table 2. Comparison of limit of detection for 12 rapid antigen detection kits to detect SARS-CoV-2 B.1.617.2 virus.

| Dilution | RT-PCR | N01 | N02 | N03 | N04 | N05 | N06 | N07 | N08 | N09 | N10 | N11 | N12 |
|----------|--------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 10⁻²      | 22.73  | +++| +++| +++| +++| +++| +++| +++| +++| ++| +++| +   | +   |
| 10⁻³      | 25.93  | +  | +  | +  | +  | +  | +  | +  | +  | -  | +  | +  | -   |
| 10⁻⁴      | 29.57  | -  | -  | -  | -  | -  | -  | -  | -  | -  | -  | -  | -   |
| 10⁻⁵      | 32.50  | -  | -  | -  | -  | -  | -  | -  | -  | -  | -  | -  | -   |
| 10⁻⁶      | -      | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND   |

The cassette showed abnormal diffusion when the specimen was applied.

The details of each kit can be referred to in Table 1. The RT-PCR and rapid antigen detection results were based on testing the serial tenfold dilution of the respiratory specimen, combined nasopharyngeal and throat swabs, obtained from a COVID-19 patient collected on 12 May 2021 (hCoV-19/Hong Kong/VM21025593/2021).

+++: Strong positive; ++: Positive; +: Weak positive; -: negative; ND: Not done.

Assessing analytical sensitivity of RAD kits

The dilution set of the specimen mentioned above was used to determine analytical sensitivity by means of limit of detection (LOD). The sensitivity of different kits can be obtained by measuring the lowest concentration of the specimen. To prepare the dilution set, serial tenfold dilution was performed for the stock of the specimen using viral transport medium (VTM). The VTM was in-house prepared by the authors and was the same VTM distributed to public and private hospitals and clinics in Hong Kong for respiratory specimen collection. Previously, the author’s results showed that there were no effect on the sensitivity of RAD kits when using either VTM or phosphate-buffered saline as diluent [27]. Each dilution point was aliquoted and stored at -70°C until further testing.

A modified sample processing method was employed to perform the RAD kits since the authors wanted to unify the input volume. Regarding the input volume, the authors previously found that RAD results were affected by the input volume. Two input volumes were evaluated, 100 and 350 μl. The result bands were more intense when using 350 μl specimen volume [25] and this sample volume was selected for accessing LOD in the present study. The operating procedures were performed according to the manufacturer’s instructions, except first by mixing 350 μl specimen volume with the kit’s extraction buffer/diluent. Only one replicate was performed for each dilution point due to limited samples and limited quantity of kits.

To note: there was a sponge to collect the specimen volume for N12. Upon completing the specimen collection, the sponge was inserted into the test cassette. The author’s preliminary evaluated the two sample processing methods by: (1) applying 350 μl specimen volume onto the sponge; and (2) applying 350 μl specimen volume directly into the test cassette. Positive results could not be obtained for (1) even though applying highest viral load of samples. It seemed to be related to absorbent effect of the sponge, a larger volume of sample should be used. On the other hand, positive results could be obtained for (2); and this sample processing method was chosen to evaluate N12 in the present study.

Virus concentrations in each dilution were estimated from cycle threshold (Ct) value as described [7]. Duplicates were performed for each dilution point and Ct values shown were the mean of both runs.

Results

The LOD results for RAD kits against SARS-CoV-2 B.1.617.2 were summarized in Table 2. All except one kit shared similar analytical sensitivity, with the lowest concentration at dilution point 10⁻³. The LOD for RT-PCR was 10⁻⁵ which was 100-fold more sensitive than the RAD kits. The LOD difference between RAD kits and RT-PCR was concordant to the author’s previous studies when using respiratory specimens of SARS-CoV-2 non-VOC strains [8,25,26].

For N10, the LOD was 10⁻². It was found that the volume of extraction buffer/diluent was the largest when comparing with other 11 kits. Around 2 ml of extraction buffer/diluent was used for N10. The decreased in sensitivity for N10 was seemed to be related to the volume of extraction buffer/diluent used and the dilution effect of the specimen.

Discussion

In the present study, the results showed that different RAD kits were capable of detecting SARS-CoV-2 B.1.617.2 virus with similar analytical sensitivity.
The SARS-CoV-2 VOCs are characterized by mutations in the S gene which can be screened by different single-nucleotide polymorphism real-time RT-PCRs with probes targeting these mutations [19]. Most RAD kits target SARS-CoV-2 N protein. This trend was also consistent in the present study. Mutations in the N protein have also been found in SARS-CoV-2 VOCs [30] which may affect the performance of RAD kits. RAD kits have also been used in other viruses. In the author’s previous findings, the reduced sensitivity of RAD in detecting influenza A(H1N1)pdm virus when comparing with seasonal A(H1N1) was most likely due to the mismatch of the swine virus origin antigen and the monoclonal antibody to the nucleoprotein of human viruses [31]. Unlike RT-PCR, the performance of different assays can be checked by aligning the sequences of primers and probes against SARS-CoV-2 viruses. Since antibodies used for RAD kits are unknown and checking the performance of RAD kits against different SARS-CoV-2 viruses was impossible. Recently, different reports showed that the performance of RAD kits were affected by the genetic background SARS-CoV-2 viruses or mutations in the N protein [32–34]. There is a lack of information whether other mutations in the N protein can affect RAD kits. The N protein of SARS-CoV-2 B.1.617.2 was characterized by three mutations, D63G, R203M and D377Y [30] when comparing with the reference strain WIV04. The author’s previous sequencing results showed that the strain used in the present study also shared these three mutations, other mutations were not found [20]. The data highlighted that these three mutations did not affect the effectiveness of RAD kits evaluated in the present study.

The purpose of this study is to estimate if the commercially available RAD kits are suitable for diagnosing SARS-CoV-2 B.1.617.2 infection; however, accurately and precise ranking of RAD kits is not the objective. It is ideal to perform more dilution points such as 1:2 and 1:5 between the two serial tenfold dilution points. In addition, each dilution point should be performed in replicates. Given that extra quantity of specimens and RAD kits were required, on top of the already strained capacity of the laboratory, it was determined that a serial tenfold dilution and single replicate were to be adopted in the study design. According to the previous results, analytical sensitivity of different RAD kits can vary hugely when comparing with RT-PCR. When serial dilution of a respiratory specimen was used to assess LOD of RAD kits, some RAD kits can be 10²-fold less sensitive than RT-PCR while the best RAD kits can be only 10²-fold less sensitive than RT-PCR [7,8]. It means that a 1000-fold difference of analytical sensitivity of RAD kits can be obtained. A dilution set of serial tenfold dilution and single replicate could fulfill the objective. In the present study, the kits selected were either based on the author’s prior evaluation experiences or products that recently emerged in the market. All except one kit shared the same LOD. The kit having one log lower than the others was mostly due to the diluent effect of the buffer used. It is encouraging to see that the performance of RAD kits improved as time goes on.

The limitations of this study include using only one SARS-CoV-2 B.1.617.2 virus to assess analytical sensitivity. The authors were incapable of using fresh samples for evaluation since viral load of different samples varied. The author’s recent analysis showed the viral load of SARS-CoV-2 samples collected from local community varied widely, Ct values ranged from 16.28 to 36.94 [39]. The viral load of different samples have to be estimated by RT-PCR first. On the other hand, SARS-CoV-2 samples had to be investigated to ensure the correct VOC selected. Using a frozen stored sample was inevitable based on this study design. However, this issue was not a matter of concern. Since the same set of dilution was used to assess different RAD kits and a fair comparison could be performed. In addition, the present study focused on assessing analytical sensitivity of RAD kits. Although we did not use clinical specimens for evaluation, LOD results correlated well with clinical sensitivity according to the author’s past studies [7,8,25,26]. In addition, the RAD kits evaluated in the present study detected lowest concentrations at Ct 25 which was in line with the recent review of summarizing 24 studies worldwide [36]. This review concluded that RAD kits were most sensitive for samples of Ct value ≤25. When there is a large demand of RAD kits, the LOD approach can provide a quick screening method. The results therefore showed that the RAD kits used in this study may be used for first-line screening of the SARS-CoV-2 B.1.617.2 variant. Finally, specificity of RAD kits was not tested for; however, the RAD kits demonstrated high specificity [2].

**Conclusion**

It is expected that many RAD kits for diagnosing SARS-CoV-2 infection are emerging and also the types of SARS-CoV-2 variants. Different studies have been reported for the performance of RAD kits against different SARS-CoV-2 variants. These results showed that SARS-CoV-2 variants demonstrated from no, minor or significant effects on RAD kits [22,23,32–34]. The performance of RAD kits should be regularly monitored so that guidance can be provided to different clinical settings.
Summary points

- The analytical sensitivity of 12 rapid antigen detection kits against SARS-CoV-2 B.1.617.2 were evaluated.
- All except one kit were 100-fold less sensitive than RT-PCR.
- The remaining kit was 1000-fold less sensitive than RT-PCR, which may be due to the dilution effect of buffer/diluent used.
- The performance of rapid antigen detection kits should be regularly monitored.

Author contributions
GCK Mak: conceptualization, methodology, validation, investigation, writing - original draft, writing - review & editing; SSY Lau: validation, investigation; KKY Wong: validation, investigation; NLS Chow: validation, investigation; CS Lau: resources, supervision; ETK Lam: supervision; KHL Ng: supervision; RCW Chan: supervision.

Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research
The authors state that they have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.

Data sharing statement
Data sharing is not applicable to the current study as the data are comprehensively described throughout this article.

References
1. WHO. Recommendations for national SARS-CoV-2 testing strategies and diagnostic capacities. Interim guidance. (2021). http://www.who.int/publications/i/item/WH0-2019-nCoV-lab-testing-2021.1-eng
2. WHO. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. Interim guidance. (2020). http://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2-infection-using-rapid-immunoassays
3. Schildgen V, Demuth S, Lusebrink J, Schildgen O. Limits and opportunities of SARS-CoV-2 antigen rapid tests: an experienced-based perspective. Pathogens 10(1), 38 (2021).
4. Demuth S, Damaschek S, Schildgen O, Schildgen V. Low sensitivity of SARS-CoV-2 rapid antigen self-tests under laboratory conditions. New Microbes New Infect. 43, 100916 (2021).
5. Platten M, Hoffmann D, Grosser R et al. SARS-CoV-2, CT-values, and infectivity-conclusions to be drawn from side observations. Viruses 13(8), 1459 (2021).
6. Osterman A, Baldauf HM, Eletreby M et al. Evaluation of two rapid antigen tests to detect SARS-CoV-2 in a hospital setting. Med. Microbiol. Immunol. 210(1), 65–72 (2021).
7. Mak GC, Cheng PK, Lau SS et al. Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. J. Clin. Virol. 129, 104500 (2020).
8. Mak GC, Lau SS, Wong KK et al. Analytical sensitivity and clinical sensitivity of the three rapid antigen detection kits for detection of SARS-CoV-2 virus. J. Clin. Virol. 133, 104684 (2020).
9. WHO. Weekly epidemiological update on COVID-19 - 21 September 2021. Edition 48. http://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---21-september-2021
10. Public Health England. Research and analysis. Variants: distribution of case data, 24 September 2021. (2021). http://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-case-data-24-september-2021
11. CDC. SARS-CoV-2 variant classifications and definitions. (2021). http://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html
12. European Centre for Disease Prevention and Control. Threat assessment brief: implications for the EU/EEA on the spread of the SARS-CoV-2 Delta (B.1.617.2) variant of concern. (2021). http://www.ecdc.europa.eu/en/publications-data/threat-assessment-emergence-and-impact-sars-cov-2-delta-variant
13. Public Health England. Increased household transmission of COVID-19 cases associated with SARS-CoV-2 variant of concern B.1.617.2: a national case-control study. https://khub.net/documents/135939561/405676950/Increased+Household+Transmission+of+%27COVID-19%27+Cases++nationwide+case+study.pdf/7f7764fb-ecb0-da31-77b3-b1a8ef7be92a
14. Dougherty K, Mannell M, Naqvi O, Matson D, Stone J. SARS-CoV-2 B.1.617.2 (Delta) variant COVID-19 outbreak associated with a gymnastics facility - Oklahoma, April–May 2021. *Mark. Mortal. Wkly Rep.* 70(28), 1004–1007 (2021).

15. Lam HY, Lam TS, Wong CH et al. The epidemiology of COVID-19 cases and the successful containment strategy in Hong Kong January to May 2020. *Int. J. Infect. Dis.* 98, 51–58 (2020).

16. Centre for Health Protection. Latest situation of cases of COVID-19. http://www.chp.gov.hk/files/pdf/local_situation_covid19_en.pdf

17. Mak GCK, Lau AWL, Chan AMY, Chan DYW, Tsang DNC. The D614G substitution in the S gene and clinical information for patients with COVID-19 detected in Hong Kong. *J. Clin. Virol.* 130, 104550 (2020).

18. Mak GCK, Lau AWL, Chan AMY, Lam ETK, Chan RCW, Tsang DNC. The surveillance of spike protein for patients with COVID-19 detected in Hong Kong in 2020. *J. Med. Virol.* 93(9), 5644–5647 (2021).

19. Tsang AKL, Mak GCK, Cheng PKC et al. Early detection of community acquired of SARS-CoV-2 lineage B.1.351 in Hong Kong. *J. Clin. Virol.* Plus 1(3), 100029 (2021).

20. Tsang AKL, Mak GCK, Leung PKL et al. Emergence of SARS-CoV-2 lineage B.1.617.2 in the local community of Hong Kong. *J. Med. Virol.* 94(1), 29–31 (2022).

21. Brown KA, Gubbay J, Hopkins J et al. S-gene target failure as a marker of variant B.1.1.7 among SARS-CoV-2 isolates in the greater Toronto area, December 2020 to March 2021. *JAMA* 325(20), 2115–2116 (2021).

22. Bekliz M, Adea K, Essaidi-Laziosi M et al. SARS-CoV-2 rapid diagnostic tests for emerging variants. *Lancet Microbe* 2(8), e351 (2021).

23. Jungnick S, Hobmaier B, Mautner L et al. Detection of the new SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in five SARS-CoV-2 rapid antigen tests (RATs), Germany, March 2021. *Euro. Surveill.* 26(16), 2100413 (2021).

24. WHO. WHO reference laboratories providing confirmatory testing for COVID-19. (2021). http://www.who.int/publications/m/item/who-reference-laboratories-providing-confirmatory-testing-for-covid-19

25. Mak GCK, Lau SSY, Wong KKY et al. Evaluation of rapid antigen detection kit from the WHO Emergency Use list for detecting SARS-CoV-2. *J. Clin. Virol.* 134, 104712 (2020).

26. Mak GCK, Lau SSY, Wong KKY et al. Evaluation of automated antigen detection test for detection of SARS-CoV-2. *Diagn. Microbiol. Infect. Dis.* 101(4), 115490 (2021).

27. Mak GCK, Lau SSY, Wong KKY et al. Comparison of analytical sensitivity of the eight rapid antigen detection kits for detecting SARS-CoV-2 virus. *J. Clin. Virol.* 144, 104994 (2021).

28. Zhou P, Yang XL, Wang XG et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 579(7798), 270–273 (2020).

29. WHO. WHO Emergency Use listing for in vitro diagnostics (IVDs) detecting SARS-CoV-2. (2020). http://www.who.int/diagnostics_laboratory/201002_eul_sars_cov2_product_list.pdf?ua=1

30. Stanford University. SARS-CoV-2 variants. (2021). https://covdb.stanford.edu/page/mutation-viewer

31. Cheng PK, Wong KK, Mak GC et al. Performance of laboratory diagnostics for the detection of influenza A(H1N1)v virus as correlated with the time after symptom onset and viral load. *J. Clin. Virol.* 47(2), 182–185 (2010).

32. Vecchio CD, Brancaccio G, Brazzale AR et al. Emergence of N antigen SARS-CoV-2 generic variants escaping detection of antigenic tests. medRxiv doi: https://doi.org/doi:10.1101/2021.03.25.21253802 (2021) (Epub ahead of print).

33. Bourassa L, Perchetti GA, Phung Q et al. A SARS-CoV-2 nucleocapsid variant that affects antigen test performance. *J. Clin. Virol.* 141, 104900 (2021).

34. Gandolfo C, Morecchiato F, Pistello M, Rossolini GM, Cusi MG. Detection of SARS-CoV-2 N protein allelic variants by rapid high-throughput CLEIA antigen assay. *J. Clin. Virol.* 142, 104942 (2021).

35. Mak GCK, Ng AYY, Lam ETK, Chan RCW, Tsang DNC. Assessment of SARS-CoV-2 viral loads in combined nasal-and-throat swabs collected from COVID-19 individuals under the Universal Community Testing Programme in Hong Kong. *J. Virol. Methods* 300, 114396 (2022).

36. Lee J, Song JU, Shim SR. Comparing the diagnostic accuracy of rapid antigen detection tests to real time polymerase chain reaction in the diagnosis of SARS-CoV-2 infection: a systematic review and meta-analysis. *J. Clin. Virol.* 144, 104985 (2021).